Jazz Pharmaceuticals plc

Total Valuation

Jazz Pharmaceuticals plc carries a market capitalization of 15.50B, placing it among publicly traded companies globally. Its enterprise value stands at 17.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Jazz Pharmaceuticals plc currently has 64.80M shares outstanding.

Valuation Ratios

Jazz Pharmaceuticals plc trades at a trailing price-to-earnings ratio of 15.81. The price-to-sales ratio is 3.23, and the price-to-book ratio stands at 3.25.

Enterprise Valuation

On an enterprise value basis, Jazz Pharmaceuticals plc trades at an EV/EBITDA multiple of 10.28 and an EV/FCF ratio of 7.99. The EV/Sales ratio of 3.87 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.54 provides insight into valuation relative to core operating earnings.

Financial Position

Jazz Pharmaceuticals plc maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.83, indicating elevated leverage, while an interest coverage ratio of 10.14 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Jazz Pharmaceuticals plc has paid -213.26M in income taxes, reflecting an effective tax rate of 13.00.

Stock Price Statistics

Jazz Pharmaceuticals plc's stock has gained approximately 90.58687% over the past 52 weeks. The 50-day moving average sits at 248.46, while the 200-day moving average is 205.13.

Income Statement

Over the trailing twelve months, Jazz Pharmaceuticals plc generated 4.60B in revenue and converted that into 940.76M in net income, yielding earnings per share of 14.44. EBITDA reached 1.73B, while operating income came in at 1.02B.

Balance Sheet

Jazz Pharmaceuticals plc holds 2.20B in cash and equivalents against 4.41B in total debt, resulting in a net debt position of 2.73B. Total book value stands at 4.80B, with working capital of 1.74B providing operational flexibility.

Cash Flow

Jazz Pharmaceuticals plc produced 1.66B in operating cash flow over the past twelve months. After subtracting -349.95M in capital expenditures, free cash flow totaled 1.31B - equivalent to 21.25 per share.

Margins

Jazz Pharmaceuticals plc operates with a gross margin of 88.42, reflecting its pricing power and cost economics. The operating margin of 22.09 and net profit margin of 20.45 provide insight into operational efficiency.

Dividends & Yields

Scores

Jazz Pharmaceuticals plc posts an Altman Z-Score of 3.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.